The DPP-IV inhibitor ER-319711 has a proliferative effect on the colonic epithelium and a minimal effect in the amelioration of colitis

Oncology Reports

Volumn 25, Issue 6, 2011, Pages 1699-1703

  Ban, Hiromitsu ^a   Bamba, Shigeki ^a   Imaeda, Hirotsugu ^a   Inatomi, Osamu ^a   Kobori, Ayako ^a   Sasaki, Masaya ^a   Tsujikawa, Tomoyuki ^a   Andoh, Akira ^a   Fujiyama, Yoshihide ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Dipeptidyl peptidase IV; Glucagon like peptide 2; Inflammatory bowel diseases

Indexed keywords

BROXURIDINE; CARBOXYMETHYLCELLULOSE; DEXTRAN SULFATE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ER 319711; GLUCAGON LIKE PEPTIDE 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL PROLIFERATION; COLITIS; COLON LENGTH; COLON MUCOSA; COLON WEIGHT; CONTROLLED STUDY; CRYPT CELL; DISEASE ACTIVITY; DRUG DOSE COMPARISON; FEMALE; MOUSE; NONHUMAN; ORGAN SIZE; ORGAN WEIGHT; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT REDUCTION;

ANIMALS; CELL PROLIFERATION; COLITIS; COLON; DIPEPTIDYL PEPTIDASE 4; ENZYME INHIBITORS; FEMALE; INTESTINAL MUCOSA; MICE; MICE, INBRED C57BL; PIPERAZINES; PURINES;

EID: 79954504906     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1223     Document Type: Article

References (23)

1. Zeeh JM, Procaccino F, Hoffmann P, et al: Keratinocyte growth factor ameliorates mucosal injury in an experimental model of colitis in rats. Gastroenterology 110: 1077-1083, 1996. (Pubitemid 26113747)
2. Cominelli F, Nast CC, Llerena R, Dinarello CA and Zipser RD: Interleukin 1 suppresses inflammation in rabbit colitis. Mediation by endogenous prostaglandins. J Clin invest 85: 582-586, 1990. (Pubitemid 20070069)
3. Tessner TG, Cohn SM, Schloemann S and Stenson WF: Prostaglandins prevent decreased epithelial cell proliferation associated with dextran sodium sulfate injury in mice. Gastroenterology 115: 874-882, 1998. (Pubitemid 28452935)
4. Qiu BS, Pfeiffer CJ and Keith JC Jr: Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats. Dig Dis Sci 41: 1625-1630, 1996. (Pubitemid 26285750)
5. Peterson RL, Wang L, Albert L, Keith JC Jr and Dorner AJ: Molecular effects of recombinant human interleukin-11 in the HLA-B27 rat model of inflammatory bowel disease. Lab Invest 78: 1503-1512, 1998. (Pubitemid 29022226)
6. Dignass AU: Mechanisms and modulation of intestinal epithelial repair. Inflamm Bowel Dis 7: 68-77, 2001.
7. Karlsson L, Lindahl P, Heath JK and Betsholtz C: Abnormal gastrointestinal development in PDGF-A and PDGFR-(alpha) deficient mice implicates a novel mesenchymal structure with putative instructive properties in villus morphogenesis. Development 127: 3457-3466, 2000.
8. Bjerknes M and Cheng H: Modulation of specific intestinal epithelial progenitors by enteric neurons. Proc Natl Acad Sci USA 98: 12497-12502, 2001. (Pubitemid 33019974)
9. Drucker DJ: Glucagon-like peptides. Diabetes 47: 159-169, 1998.
10. Drucker DJ, Yusta B, Boushey RP, DeForest L and Brubaker PL: Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am J Physiol 276: G79-G91, 1999. (Pubitemid 29063603)
11. Drucker DJ: Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 122: 531-544, 2002.
12. Drucker DJ: Gut adaptation and the glucagon-like peptides. Gut 50: 428-435, 2002.
13. Jeppesen PB, Hartmann B, Thulesen J, et al: Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 120: 806-815, 2001. (Pubitemid 32193176)
14. Yamazaki K, Yasuda N, Inoue T, et al: 7-But-2-ynyl-9-(6-methoxy-pyridin- 3-yl)-6-piperazin-1-yl-7,9-dihydro-purin -8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity. J Pharmacol Exp Ther 319: 1253-1257, 2006.
15. Cooper HS, Murthy SN, Shah RS and Sedergran DJ: Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 69: 238-249, 1993.
16. Dieleman LA, Ridwan BU, Tennyson GS, Beagley KW, Bucy RP and Elson CO: Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 107: 1643-1652, 1994. (Pubitemid 24357616)
17. Edholm T, Degerblad M, Gryback P, et al: Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis. Neurogastroenterol Motil 22: 1191-1200, 2010.
18. Deacon CF: Therapeutic strategies based on glucagon-like peptide 1. Diabetes 53: 2181-2189, 2004.
19. Deacon CF, Ahren B and Holst JJ: Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes? Expert Opin Investig Drugs 13: 1091-1102, 2004.
20. Nauck MA, Meininger G, Sheng D, Terranella L and Stein PP: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 9: 194-205, 2007.
21. Harada N, Yamada Y, Tsukiyama K, et al: A novel GIP receptor splice variant influences GIP sensitivity of pancreatic beta-cells in obese mice. Am J Physiol 294: E61-E68, 2008.
22. Kos K, Baker AR, Jernas M, et al: DPP-IV inhibition enhances the antilipolytic action of NPY in human adipose tissue. Diabetes Obes Metab 11: 285-292, 2009.
23. Yazbeck R, Howarth GS, Geier MS, Demuth HU and Abbott CA: Inhibiting dipeptidyl peptidase activity partially ameliorates colitis in mice. Front Biosci 13: 6850-6858, 2008.